Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety.
about
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.Immunogenicity, efficacy and safety of Nuwiq(®) (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.PK-guided personalized prophylaxis with Nuwiq(®) (human-cl rhFVIII) in adults with severe haemophilia A.Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics.Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.A close insight to factor VIII inhibitor in the congenital hemophilia A.Emerging drugs for the treatment of hemophilia A and B.Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.Production of recombinant coagulation factors: Are humans the best host cells?Current and emerging factor VIII replacement products for hemophilia A.Efficacy and safety of Nuwiq(®) (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures.Simoctocog alfa for the treatment of hemophilia A.Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
P2860
Q37153245-52A9E7D7-4453-4CAB-AB58-38350158757DQ38620816-2848AA8C-DC95-4551-B414-CDE05F7F744EQ38705742-930BC510-65C7-4A64-B105-D6AA5A1DEFF3Q38720560-CD71CE43-F225-410B-B2B0-FD93AE3EDDA0Q38725317-A77D3841-320C-40DA-A052-BCF4A4B2356AQ38818573-2F6FEBCC-2A1D-4318-B9A7-87B89D1917FAQ38883211-7CB767E1-C31F-491C-9046-FD4402055450Q38933707-DBAEC74F-0405-41F1-BD76-526D42DD363DQ38944642-1CEF267A-7164-4E82-9598-F634E31EEE13Q39170433-5F060830-3816-497A-84DB-D8C6BF6A9F2EQ42375640-52EBC9EB-BD35-498F-8BCE-DF083871212DQ45873356-8C8B1ADE-0F4D-4DEA-8BC3-84FB810F0AA9Q45873366-467D8DFF-F45A-414C-A49F-DD1548CF00A7Q45874491-7F9752E8-E055-4272-BD1C-0ED59D3B43C0
P2860
Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Novel, human cell line-derived ...... philia A: efficacy and safety.
@en
type
label
Novel, human cell line-derived ...... philia A: efficacy and safety.
@en
prefLabel
Novel, human cell line-derived ...... philia A: efficacy and safety.
@en
P2093
P2860
P921
P356
P1433
P1476
Novel, human cell line-derived ...... philia A: efficacy and safety.
@en
P2093
A Huth-Kühne
E Tuddenham
I Pabinger
J Oldenburg
K Holstein
M von Depka
P2860
P356
10.1111/HAE.12793
P577
2015-08-28T00:00:00Z